An anti-ganglioside antibody-secreting hybridoma induces neuropathy in mice

Annals of Neurology

Volumn 56, Issue 2, 2004, Pages 228-239

  Sheikh, Kazim A ^a,b   Zhang, Gang ^a   Gong, Yanpin ^a   Schnaar, Ronald L ^a   Griffin, John W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD1A ANTIBODY; GANGLIOSIDE GM1 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACUTE MOTOR AXONAL NEUROPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SECRETING HYBRIDOMA; ANTIBODY TITER; ARTICLE; BLOOD BRAIN BARRIER; BLOOD NERVE BARRIER; CAMPYLOBACTER; CONTROLLED STUDY; GUILLAIN BARRE SYNDROME; HYBRIDOMA; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; NERVE FIBER; NERVE FIBER DEGENERATION; NEUROPATHY; NONHUMAN; PASSIVE IMMUNIZATION; PASSIVE TRANSPORT; PATHOGENESIS; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; DISEASE MODELS, ANIMAL; G(M1) GANGLIOSIDE; GANGLIOSIDES; HYBRIDOMAS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MICE; MICE, INBRED STRAINS; NERVE DEGENERATION; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; SPECIES SPECIFICITY; SPINAL CORD;

EID: 3843073116     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20173     Document Type: Article

References (72)

1. Hughes RA, Hadden RD, Gregson NA, et al. Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol 1999;100:74-97.
2. Willison HJ, Yuki N. Peripheral neuropathies and antiglycolipid antibodies. Brain 2002;125:2591-2625.
3. Yuki N. Current cases in which epitope mimicry is considered a component cause of autoimmune disease: Guillain-Barre syndrome. Cell Mol Life Sci 2000;57:527-533.
4. Yuki N, Yoshino H, Sato S, et al. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990;40:1900-1902.
5. Ho TW, Mishu B, Li CY, et al. Guillain-Barre syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597-605.
6. Yuki N, Takahashi M, Tagawa Y, et al. Association of Campylobacter jejunni serotype with antiganglioside antibody in Guillain-Barre syndrome and Fisher's syndrome. Ann Neurol 1997;42:28-33.
7. Yuki N, Yamada M, Sato S, et al. Association of IgG anti-GD1a antibody with severe Guillain-Barre syndrome. Muscle Nerve 1993;16:642-647.
8. Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. Ann Neurol 1999;45:168-173.
9. Yuki N, Taki T, Handa S. Antibody to Ga1NAc-GD1a and Ga1NAc-GM1b in Guillain-Barre syndrome subsequent to Campylabacter jejuni enteritis. J Neuroimmunol 1996;71:155-161.
10. Kaida K, Kusunoki S, Kamakura K, et al. Guillain-Barre syndrome with antibody to a ganglioside, N-acetylgalactosaminyl GD1a. Brain 2000;123:116-124.
11. Kusunoki S, Iwamori M, Chiba A, et al. GM1b is a new member of antigen for serum antibody in Guillain-Barré syndrome. Neurology 1996;47:237-242.
12. Kusunoki S, Chiba A, Kon K, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barre syndrome. Ann Neurol 1994;35:570-576.
13. Chiba A, Kusunoki S, Shimizu T, et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-679.
14. Willison HJ, Veitch J, Patterson G, et al. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 1993;56:204-206.
15. Yuki N, Sato S, Tsuji S, et al. Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Neurology 1993;43:4l4-417.
16. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178:1771-1775.
17. 1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994;36:791-793.
18. Nachamkin I, Liu J, Li M, et al. Campylobacter jejuni from patients with Guillain-Barre syndrome preferentially expresses a GD(1a)-like epitope. Infect Immun 2002;70:5299-5303.
19. Sheikh KA, Nachamkin I, Ho TW, et al. Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome: molecular mimicry and host susceptibility. Neurology 1998;51:371-378.
20. Aspinall GO, McDonald AG, Raju TS, et al. Chemical structures of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides. Eur J Biochem 1993;213:1017-1027.
21. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barte syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-1917.
22. Sheikh KA, Deerinck TJ, Ellisman MH, et al. The distribution of ganglioside-like moieties in peripheral nerves. Brain 1999;122:449-460.
23. Gong Y, Tagawa Y, Lunn MP, et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 2002;125:2491-2506.
24. Hafer-Macko C, Hsieh S-T, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-644.
25. Ho T, Hsieh S, Nachamkin I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997;48:717-724.
26. Goodyear CS, O'Hanlon GM, Plomp JJ, et al. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 1999;104:697-708. Published erratum appears in J Clin Invest 1999;104:1771.
27. Goodyear CS, O'Hanlon GM, Plomp JJ, et al. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 1999;104:697-708. Published erratum appears in J Clin Invest 1999;104:1771.
28. Lunn MP, Johnson LA, Fromholt SE, et al. High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: reexamination of GD1a immunolocalization. J Neurochem 2000;75:404-412.
29. Bowes T, Wagner ER, Boffey J, et al. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barre syndrome. Infect Immun 2002;70:5008-5018.
30. Ang CW, De Klerk MA, Endtz HP, et al. Guillain-Barre syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b antibodies in rabbits. Infect Immun 2001;69:2462-2469.
31. Wirguin I, Briani C, Suturkova-Milosevic L, et al. Induction of anti-GM1 ganglioside antibodies by Campylobacter jejuni lipopolysaccharides. J Neuroimmunol 1997;78:138-142.
32. Gregson NA, Hammer CT. Some immunological properties of antisera raised against the trisialoganglioside GT1B. Mol Immunol 1982;19:543-550.
33. Saez-Torres I, Diaz-Villoslada P, Martinez-Caceres E, et al. Gangliosides do not elicit experimental autoimmune encephalomyelitis in Lewis rats and SJL mice. J Neuroimmunol 1998;84:24-29.
34. Lopez PH, Villa AM, Sica RE, et al. High affinity as a disease determinant factor in anti-GM(1) antibodies: comparative characterization of experimentally induced vs. disease- associated antibodies. J Neuroimmunol 2002;128:69-76.
35. Hadden RD, Gregson NA, Gold R, et al. Guillain-Barte syndrome serum and anti-Campylobacter antibody do not exacerbate experimental autoimmune neuritis. J Neuroimmunol 2001;119:306-316.
36. Kusunoki S, Shimizu J, Chiba A, et al. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 1996;39:424-431.
37. Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001;49:712-720.
38. Kusunoki S, Hitoshi S, Kaida K, et al. Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. Ann Neurol 1999;45:400-403.
39. Kusunoki S, Hitoshi S, Kaida K, et al. Degeneration of rabbit sensory neurons induced by passive transfer of anti-GD1b antiserum. Neurosci Lett 1999;273:33-36.
40. Liu Y, Wada R, Kawai H, et al. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J Clin Invest 1999;103:497-505.
41. Barnstable CJ, Bodmer WF, Brown G, et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978;14:9-20.
42. Brodsky FM, Parham P. Monomorphic anti-HLA-A,B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants. J Immunol 1982;128:129-135.
43. Spatz LA, Williams M, Brender B, et al. DNA sequence analysis and comparison of the variable heavy and light chain regions of two IgM, monoclonal, anti-myelin associated glycoprotein antibodies. J Neuroimmunol 1992;36:29-39.
44. O'Shannessy DJ, Willison HJ, Inuzuka T, et al. The species distribution of nervous system antigens that react with anti-myelin-associated glycoprotein antibodies. J Neuroimmunol 1985;9:255-268.
45. Schnaar RL, Fromholt SE, Gong Y, et al. IgG-class mouse monoclonal antibodies to major brain gangliosides. Anal Biochem 2002;302:276-284.
46. Gillette RW. Alternatives to pristane priming for ascitic fluid and monoclonal antibody production. J Immunol Methods 1987;99:21-23.
47. Tekolf WA, Shaw S. In vitro generation of cytotoxic cells specific for human minor histocompatibility antigens by lymphocytes from a normal donor potentially primed during pregnancy. J Exp Med 1983;157:2172-2177.
48. Tagawa Y, Yuki N, Hirata K. Anti-SGPG antibody in CIDP: nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy. Muscle Nerve 2000;23:895-899.
49. Bao L, Lindgren JU, Zhu Y, et al. Exogenous soluble tumor necrosis factor receptor type I ameliorates murine experimental autoimmune neuritis. Neurobiol Dis 2003;12:73-81.
50. Sheikh KA, Lui Y, Kawai H, et al. Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Natl Acad Sci USA 1999;96:7532-7537.
51. Salacinski PR, McLean C, Sykes JE, et al. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (Iodogen). Anal Biochem 1981;117:136-146.
52. Hadden RD, Gregson NA, Gold R, et al. Accumulation of immunoglobulin across the "blood-nerve barrier" in spinal roots in adoptive transfer experimental autoimmune neuritis. Neuropathol Appl Neurobiol 2002;28:489-497.
53. Roberts M, Willison HJ, Vincent A, et al. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol 1995;38:111-118.
54. Buchwald B, Toyka KV, Zielasek J, et al. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barre syndrome: a macro-patch-clamp study. Ann Neurol 1998;44:913-922.
55. Plomp JJ, Molenaar PC, O'Hanlon GM, et al. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol 1999;45:189-199. Published erratum appears in Ann Neurol 1999;45:823.
56. Plomp JJ, Molenaar PC, O'Hanlon GM, et al. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol 1999;45:189-199. Published erratum appears in Ann Neurol 1999;45:823.
57. Pollard JD, Westland KW, Harvey GK, et al. Activated T cells of nonneural specificity open the blood-nerve barrier to circulating antibody. Ann Neurol 1995;37:467-475.
58. Spies JM, Westland KW, Bonner JG, et al. Intraneural activated T cells cause focal breakdown of the blood-nerve barrier. Brain 1995;118:857-868.
59. Spies JM, Pollard JD, Bonner JG, et al. Synergy between antibody and P2-reactive T cells in experimental allergic neuritis. J Neuroimmunol 1995;57:77-84.
60. Bergman I, Basse PH, Barmada MA, et al. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol Immunother 2000;49:259-266.
61. Ong GL, Mattes MJ. Mouse strains with typical mammalian levels of complement activity. J Immunol Methods 1989;125:147-158.
62. Zhang G, Lopez PH, Li CY, et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004;127:1085-1100.
63. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol 1996;39:17-28.
64. Griffin JW, Li CY, Ho TW, et al. Guillain-Barre syndrome in northern China: the spectrum of neuropathologic changes in clinically defined cases. Brain 1995;118:577-595.
65. Marcus D, Latov N, Hsi B. Measurement and significance of antibodies against GM1 ganglioside. J Neuroimmunol 1989;25:255-259.
66. Westland KW, Pollard JD, Sander S, et al. Activated non-neural specific T cells open the blood-brain barrier to circulating antibodies. Brain 1999;122:1283-1291.
67. Yan WX, Taylor J, Andrias-Kauba S, et al. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000;47:765-775.
68. Linington C, Bradi M, Lassmann H, et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/ oligodendrocyte glycoprotein. Am J Pathol 1988;130:443-454.
69. Litzenburger T, Fassler R, Bauer J, et al. B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J Exp Med 1998;188:169-180.
70. Toyka KV, Drachman DB, Griffin DE, et al. Myasthenia gravis: study of humoral immune mechanisms by transfer to mice. N Engl J Med 1977;296:125-131.
71. Fukunaga H, Engel AG, Lang B, et al. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 1983;80:7636-7640.
72. Lang B, Newsom-Davis J, Prior C, et al. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol 1983;344:335-345.